About Cytoplasmic phosphatidylinositol transfer protein 1
Cytoplasmic phosphatidylinositol transfer protein 1 (PITPNC1) is a protein
from Homo sapiens identified by UniProt accession
Q9UKF7, 332 residues long.
MolForge cross-references it against 0 known binders and
78 disease associations.
Target properties
| Protein name | Cytoplasmic phosphatidylinositol transfer protein 1 |
|---|
| UniProt accession | Q9UKF7 |
|---|
| Gene | PITPNC1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 332 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (78)
Diseases linked to this target (Open Targets).
- chronotype measurement · score 0.45
- BMI-adjusted waist-hip ratio · score 0.41
- gut microbiome measurement · score 0.35
- blood urea nitrogen measurement · score 0.33
- osteoarthritis · score 0.31
- YKL40 measurement · score 0.31
- inflammatory biomarker measurement · score 0.31
- DNA methylation · score 0.31
- waist-hip ratio · score 0.29
- glomerular filtration rate · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UKF7-F1 | alphafold | PREDICTED | 82.04 | — |
Amino-acid sequence (332 residues)
MLLKEYRICM PLTVDEYKIG QLYMISKHSH EQSDRGEGVE VVQNEPFEDP HHGNGQFTEK RVYLNSKLPS WARAVVPKIF YVTEKAWNYY PYTITEYTCS FLPKFSIHIE TKYEDNKGSN DTIFDNEAKD VEREVCFIDI ACDEIPERYY KESEDPKHFK SEKTGRGQLR EGWRDSHQPI MCSYKLVTVK FEVWGLQTRV EQFVHKVVRD ILLIGHRQAF AWVDEWYDMT MDEVREFERA TQEATNKKIG IFPPAISISS IPLLPSSVRS APSSAPSTPL STDAPEFLSV PKDRPRKKSA PETLTLPDPE KKATLNLPGM HSSDKPCRPK SE
Explore Cytoplasmic phosphatidylinositol transfer protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets